Home Cart Sign in  
Chemical Structure| 146062-49-9 Chemical Structure| 146062-49-9

Structure of MSDC 0160
CAS No.: 146062-49-9

Chemical Structure| 146062-49-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

MSDC-0160 is a prototype mTOR-modulating insulin sensitizer being studied to treat diabetes and Alzheimer's disease.

Synonyms: Mitoglitazone; CAY10415

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of MSDC 0160

CAS No. :146062-49-9
Formula : C19H18N2O4S
M.W : 370.42
SMILES Code : O=C(N1)SC(CC2=CC=C(OCC(C3=NC=C(CC)C=C3)=O)C=C2)C1=O
Synonyms :
Mitoglitazone; CAY10415
MDL No. :MFCD00916084
InChI Key :IRNJSRAGRIZIHD-UHFFFAOYSA-N
Pubchem ID :10429242

Safety of MSDC 0160

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of MSDC 0160

RTK

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
CML CD34+CD38- cells 50 μM 24 hours MSDC-0160 inhibited glucose oxidation in the primitive CD34+CD38- population Nat Commun. 2023 Aug 17;14(1):4634
CML CD34+ cells 20 μM and 100 μM 24 hours MSDC-0160 reduced glucose contribution to TCA cycle metabolites in a dose-dependent manner Nat Commun. 2023 Aug 17;14(1):4634
human islet cells 1-50 μM 24 hours To evaluate the effects of MSDC-0160 on restoring insulin/IGF-1 sensitivity and insulin content in human β-cells. Results showed that MSDC-0160 treatment increased AMPK activity, reduced mTOR activity, restored IGF-1-induced phosphorylation of Akt and GSK-3, and increased Pdx1 protein expression. PLoS One. 2013 May 1;8(5):e62012
Human retinal endothelial cells (HRECs) 1 μM and 10 μM MSDC-0160 (MPC inhibitor) did not significantly affect HREC barrier function or cell spreading behavior. J Biol Chem. 2025 May;301(5):108472

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice, rats, and cynomolgus monkeys Oral 50, 100, or 150 mg Once daily for 12 weeks To evaluate the efficacy and safety of MSDC-0160 in patients with type 2 diabetes. Results showed that MSDC-0160 was comparable to pioglitazone in lowering fasting glucose and HbA1c levels, but with fewer side effects such as fluid retention and weight gain. Clin Pharmacol Ther. 2013 Apr;93(4):352-9
Mice Sciatic nerve transection model Local administration 100 μM 1 day (24 hours) To evaluate the effect of MSDC-0160 on ATP levels and Wallerian degeneration after sciatic nerve transection. Results showed that MSDC-0160 did not significantly alter ATP levels or promote Wallerian degeneration on the transection side. eNeuro. 2023 Mar 20;10(3):ENEURO
Rats and mice AAV αSyn overexpression model and PFF αSyn seeding model Oral 30 mg/kg Once daily for 4 months To evaluate the effects of MSDC-0160 on αSyn aggregation. In the AAV αSyn overexpression model, MSDC-0160 increased αSyn aggregation; in the PFF seeding model, MSDC-0160 increased αSyn pathology burden at 5 weeks but showed no significant difference at 13 weeks. Free Neuropathol. 2020;1:33
NRG-W41 mice Patient-derived xenograft model Oral gavage 30 mg/kg/day Once daily for 4 weeks Combination of MSDC-0160 with imatinib significantly reduced therapy-resistant CD34+CD38- CML cells Nat Commun. 2023 Aug 17;14(1):4634

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.70mL

0.54mL

0.27mL

13.50mL

2.70mL

1.35mL

27.00mL

5.40mL

2.70mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories